Home >> Tag Archives: Array BioPharma—

Tag Archives: Array BioPharma—

FDA approves Braftovi + Mektovi

August 2018—Array BioPharma announced that the FDA has approved Braftovi (encorafenib) capsules in combination with Mektovi (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation, as detected by an FDA-approved test.

Read More »
X